The Design and Preclinical Evaluation of a Single-Label Bimodal Nanobody Tracer for Image-Guided Surgery.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
26 02 2021
Historique:
received: 26 01 2021
revised: 16 02 2021
accepted: 23 02 2021
entrez: 3 3 2021
pubmed: 4 3 2021
medline: 16 9 2021
Statut: epublish

Résumé

Intraoperative guidance using targeted fluorescent tracers can potentially provide surgeons with real-time feedback on the presence of tumor tissue in resection margins. To overcome the limited depth penetration of fluorescent light, combining fluorescence with SPECT/CT imaging and/or gamma-ray tracing has been proposed. Here, we describe the design and preclinical validation of a novel bimodal nanobody-tracer, labeled using a "multifunctional single attachment point" (MSAP) label, integrating a Cy5 fluorophore and a diethylenetriaminepentaacetic acid (DTPA) chelator into a single structure. After conjugation of the bimodal MSAP to primary amines of the anti-HER2 nanobody 2Rs15d and

Identifiants

pubmed: 33652977
pii: biom11030360
doi: 10.3390/biom11030360
pmc: PMC7996797
pii:
doi:

Substances chimiques

Radiopharmaceuticals 0
Single-Domain Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fonds Wetenschappelijk Onderzoek
ID : FWOSB74
Organisme : Stichting Tegen Kanker
ID : FAF-C/2016/813
Organisme : Oncology Research Center of the Universitair Ziekenhuis Brussel
ID : OZR3015

Références

J Am Chem Soc. 2012 Nov 28;134(47):19338-41
pubmed: 23137147
J Nucl Med. 2018 Jun;59(6):986-992
pubmed: 29449447
Cancer J. 2008 May-Jun;14(3):191-7
pubmed: 18536559
Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):7973-7
pubmed: 1518823
Chem Commun (Camb). 2008 Oct 21;(39):4792-4
pubmed: 18830495
Mol Diagn Ther. 2013 Apr;17(2):85-99
pubmed: 23529353
J Nucl Med. 2020 Feb;61(2):234-241
pubmed: 31481575
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
Radiology. 2015 May;275(2):521-9
pubmed: 25521776
Theranostics. 2018 Nov 12;8(21):5903-5914
pubmed: 30613270
J Nucl Med. 2013 May;54(5):776-84
pubmed: 23487015
J Nucl Med. 2020 Jan;61(1):13-19
pubmed: 31712326
Annu Rev Immunol. 2018 Apr 26;36:695-715
pubmed: 29490163
Mol Pharm. 2017 Apr 3;14(4):1145-1153
pubmed: 28245129
Clin Cancer Res. 2020 Nov 15;26(22):5934-5942
pubmed: 32900795
Eur Urol. 2020 Dec;78(6):865-872
pubmed: 32950298
Theranostics. 2018 Mar 8;8(8):2161-2170
pubmed: 29721070
Lancet Oncol. 2019 Jul;20(7):e354-e367
pubmed: 31267970
FASEB J. 2011 Jul;25(7):2433-46
pubmed: 21478264
J Control Release. 2020 Jan 10;317:34-42
pubmed: 31734445
Clin Cancer Res. 2017 Nov 1;23(21):6616-6628
pubmed: 28751451
Chembiochem. 2012 May 7;13(7):1039-45
pubmed: 22505018
Antibodies (Basel). 2019 Jan 11;8(1):
pubmed: 31544818
Theranostics. 2014 Jan 29;4(4):386-98
pubmed: 24578722
Bioconjug Chem. 2016 May 18;27(5):1253-8
pubmed: 27074375
Biol Chem. 2019 Feb 25;400(3):323-332
pubmed: 30240352
JAMA. 2012 Sep 12;308(10):1007-14
pubmed: 22968889
PLoS One. 2013;8(1):e48324
pubmed: 23326303
Data Brief. 2016 Jan 06;6:542-9
pubmed: 26904717
Bioconjug Chem. 2011 May 18;22(5):859-64
pubmed: 21480671
Mol Imaging. 2012 Feb;11(1):33-46
pubmed: 22418026
Bioconjug Chem. 2014 May 21;25(5):979-88
pubmed: 24815083
Oncotarget. 2015 Jun 10;6(16):14260-73
pubmed: 25895028
Oral Oncol. 2017 Mar;66:1-8
pubmed: 28249642
Contrast Media Mol Imaging. 2016 Sep;11(5):328-339
pubmed: 27147480
Br J Radiol. 2016 Jun;89(1062):20150797
pubmed: 26943463
J Nucl Med. 2017 May;58(5):706-710
pubmed: 28126888
J Nucl Med. 2018 Jun;59(6):885-891
pubmed: 29545374
EJNMMI Res. 2011 Dec 01;1(1):31
pubmed: 22214225
Lab Anim (NY). 2007 Sep;36(8):40-3
pubmed: 17721532
Contrast Media Mol Imaging. 2011 Mar-Apr;6(2):85-92
pubmed: 20936711
Mol Imaging Biol. 2018 Jun;20(3):361-367
pubmed: 29090412
Nucl Med Biol. 2016 Apr;43(4):247-52
pubmed: 27067045
Eur Urol. 2019 Apr;75(4):659-666
pubmed: 29625755
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837

Auteurs

Pieterjan Debie (P)

Laboratory for In Vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Noemi B Declerck (NB)

Laboratory for In Vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Danny van Willigen (D)

Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University, 2311 Leiden, The Netherlands.

Celine M Huygen (CM)

Laboratory for In Vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Bieke De Sloovere (B)

Laboratory for In Vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Lukasz Mateusiak (L)

Laboratory for In Vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Jessica Bridoux (J)

Laboratory for In Vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Janik Puttemans (J)

Laboratory for In Vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Nick Devoogdt (N)

Laboratory for In Vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Fijs W B van Leeuwen (FWB)

Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University, 2311 Leiden, The Netherlands.

Sophie Hernot (S)

Laboratory for In Vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH